<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Injection sclerotherapy techniques for the treatment of telangiectasias, reticular veins, and small varicose veins</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Injection sclerotherapy techniques for the treatment of telangiectasias, reticular veins, and small varicose veins</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Injection sclerotherapy techniques for the treatment of telangiectasias, reticular veins, and small varicose veins</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sherry Scovell, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Eidt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph L Mills, Sr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Dover, MD, FRCPC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Injection sclerotherapy is a minimally invasive percutaneous technique using chemical irritants to close unwanted superficial veins [<a href="#rid1">1,2</a>]. Sclerotherapy is primarily used in the treatment of telangiectasias, reticular veins, and small nonaxial varicose veins (&lt;6 mm), which may or may not be symptomatic, and even in the absence of symptoms can be a source of significant distress to some patients. </p><p>Sclerotherapy techniques for the treatment of telangiectasias, reticular veins, and small, nonaxial varicose veins (&lt;6 mm) are reviewed. The use of sclerosing agents to treat superficial venous insufficiency of the saphenous veins or perforator veins is reviewed separately. (See  <a class="medical medical_review" href="/d/html/129600.html" rel="external">"Nonthermal, nontumescent ablation techniques for the treatment of lower extremity superficial venous insufficiency"</a>.)</p><p>Alternative approaches to treatment of telangiectasia, reticular veins, and small, nonaxial varicose veins (&lt;6 mm) are also reviewed separately. (See  <a class="medical medical_review" href="/d/html/8176.html" rel="external">"Laser and light therapy of lower extremity telangiectasias, reticular veins, and small varicose veins"</a> and  <a class="medical medical_review" href="/d/html/121344.html" rel="external">"Approach to treating symptomatic superficial venous insufficiency", section on 'Ambulatory phlebectomy'</a>.)</p><p class="headingAnchor" id="H1063602276"><span class="h1">VENOUS ANATOMY</span><span class="headingEndMark"> — </span>The superficial veins of the lower extremity are classified as axial or nonaxial. The axial veins include the great, small, and accessory saphenous veins  (<a class="graphic graphic_figure graphicRef55019 graphicRef52340" href="/d/graphic/55019.html" rel="external">figure 1A-B</a>). </p><p>Nonaxial superficial veins, including the intersaphenous veins, lateral veins, and other nonaxial veins, have variable anatomy. (See  <a class="medical medical_review" href="/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders", section on 'Superficial venous system (As)'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>Telangiectasias are a confluence of dilated intradermal venules &lt;1 mm in diameter  (<a class="graphic graphic_picture graphicRef62119 graphicRef70438" href="/d/graphic/62119.html" rel="external">picture 1A-B</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reticular veins are dilated bluish subdermal veins 1 to 3 mm in diameter  (<a class="graphic graphic_picture graphicRef62119 graphicRef70438" href="/d/graphic/62119.html" rel="external">picture 1A-B</a>). They are usually tortuous. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Varicose veins are subcutaneous dilated veins 3 mm or greater in size  (<a class="graphic graphic_picture graphicRef56463 graphicRef68551" href="/d/graphic/56463.html" rel="external">picture 2A-B</a>). Smaller varicose veins (&lt;6 mm) typically involve saphenous vein tributaries or nonsaphenous superficial leg veins. </p><p></p><p>The deep veins of the lower extremity  (<a class="graphic graphic_figure graphicRef75219" href="/d/graphic/75219.html" rel="external">figure 2</a>) are contained within the muscle compartments bounded by the muscle fascia. (See  <a class="medical medical_review" href="/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders", section on 'Deep venous system (Ad)'</a>.)</p><p>Perforator veins are those veins that traverse the muscular fascia to connect superficial veins with the deep veins. These are located anteriorly, posteriorly, laterally, and medially in both the thigh and calf. (See  <a class="medical medical_review" href="/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders"</a> and  <a class="medical medical_review" href="/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders", section on 'Perforator veins (Ap)'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Superficial telangiectasias, reticular veins, and varicose veins are the visible signs of chronic venous disease and can occur in the presence or absence of either symptoms or an underlying functional venous disorder (ie, venous reflux) [<a href="#rid2">2</a>]. Candidates for sclerotherapy are patients with persistent symptoms and signs of chronic venous disease refractory to medical management. (See  <a class="medical medical_review" href="/d/html/8181.html" rel="external">"Overview of lower extremity chronic venous disease", section on 'Approach by clinical severity'</a> and  <a class="medical medical_review" href="/d/html/121344.html" rel="external">"Approach to treating symptomatic superficial venous insufficiency", section on 'Candidates for venous intervention'</a>.)</p><p>While telangiectasias, reticular veins, and small, nonaxial varicose veins (&lt;6 mm) may be symptomatic, most are asymptomatic, but patients often find the cosmetic appearance of their veins distressing. Sclerotherapy can generally be performed following physical examination in those who are asymptomatic without further diagnostic studies, as these patients are less likely to have underlying venous reflux compared with symptomatic patients [<a href="#rid2">2,3</a>]. (See <a class="local">'Patient counseling'</a> below.)</p><p>Patients with stigmata of recent venous bleeding or recurrent bleeding from telangiectasias, reticular veins, and small, nonaxial varicose veins (&lt;6 mm) may benefit from sclerotherapy of that vein site [<a href="#rid4">4,5</a>]. After bleeding is controlled by elevation and direct pressure over the bleeding varicose vein, duplex examination is performed [<a href="#rid6">6</a>]. Additional treatments may be warranted to manage superficial venous reflux. However, sclerotherapy of veins that have bled is often successful even in the presence of venous reflux [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/8181.html" rel="external">"Overview of lower extremity chronic venous disease", section on 'Bleeding'</a>.) </p><p class="headingAnchor" id="H4"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>Sclerotherapy should not be performed in patients who have signs of acute venous thrombosis (superficial, deep). While other ablation techniques have been investigated for managing superficial venous thrombosis, the results of these studies cannot be generalized to sclerotherapy. </p><p>We agree with venous guidelines that pregnant individuals should defer treatment until after delivery [<a href="#rid7">7,8</a>]. Sclerosing agents are not approved for use in the US during pregnancy. Moreover, telangiectasis, reticular veins, and small, nonaxial varicose veins (&lt;6 mm) will often regress in the months following delivery and not require any treatment at all [<a href="#rid9">9,10</a>]. There are some studies that suggest that sclerosing solutions do cross the placenta, although their specific effects are not well characterized. While available studies have not identified adverse maternal or fetal outcomes [<a href="#rid8">8,11</a>], sclerotherapy of telangiectasias, reticular veins, and small, nonaxial varicose veins is considered an elective cosmetic procedure, and any risk would not be justified. </p><p>Diabetes and evidence of peripheral artery disease are relative contraindications due to an increased risk for wound complications, but this depends upon the nature and extent of sclerotherapy being considered and the presence of ischemia.</p><p>A history of migraine headache and patent foramen ovale are relative contraindications to foam sclerotherapy due to a risk for microembolism. The risk appears to be limited to physician-compounded foam using room air due to the nitrogen content in room air. Physician-compounded foam made with carbon dioxide or a mixture of carbon dioxide/oxygen does not necessarily carry this contraindication. Microembolism has not been reported with proprietary microfoam formulations. (See <a class="local">'Formulations'</a> below and  <a class="medical medical_review" href="/d/html/129600.html" rel="external">"Nonthermal, nontumescent ablation techniques for the treatment of lower extremity superficial venous insufficiency", section on 'Sclerotherapy'</a> and  <a class="medical medical_review" href="/d/html/129600.html" rel="external">"Nonthermal, nontumescent ablation techniques for the treatment of lower extremity superficial venous insufficiency", section on 'Visual and other neurologic disturbances'</a>.)</p><p class="headingAnchor" id="H127214858"><span class="h2">Alternatives</span><span class="headingEndMark"> — </span>Vein clearance rates and overall patient satisfaction generally favors sclerotherapy over cutaneous laser for reticular veins or larger varicose veins [<a href="#rid12">12,13</a>]. Once reticular or larger varicose veins have been cleared, clearance rates for telangiectasias are comparable. Also, due to the risk of longstanding hypopigmentation from laser and light treatments, liquid sclerotherapy is a more appropriate choice for patients with Fitzpatrick skin types IV, V, and VI  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 1</a>). Laser/light treatments are recommended for patients who have failed sclerotherapy, those with veins too small to access (&lt;0.3 mm; smaller than 30-gauge needle) or poor outcome, patients with postsclerotherapy matting, needle-phobic patients, and patients who are allergic to sclerosant agents. Laser/light treatment is also preferred for vessels located at or below the ankle regions, which are more prone to ulceration with sclerotherapy due to increased risk of intra-arterial injection [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/8176.html" rel="external">"Laser and light therapy of lower extremity telangiectasias, reticular veins, and small varicose veins"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">PATIENT COUNSELING</span><span class="headingEndMark"> — </span>The decision to offer sclerotherapy depends upon symptoms, response to conservative therapy, extent of lower extremity disease, and likelihood of providing a durable benefit, either with respect to appearance or improvement in symptoms. For all patients, it is important to address patient expectations, potential adverse effects, potential failure of treatment, and the complications of treatment. Sclerotherapy of telangiectasias, reticular veins, and small, nonaxial varicose veins is generally considered a cosmetic treatment and in the United States is typically not covered by insurance, though occasionally it will be reimbursed if a vein has bled. </p><p>Patients treated for cosmetic purposes need to be carefully counseled prior to treatment. Patients must understand that the results of cosmetic sclerotherapy are unpredictable in spite of expert technique, and some patients with favorable conditions (Fitzpatrick skin type I and II, ideal injections)  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 1</a>) may still have results they deem unsatisfactory. Patients should be informed that veins will lighten and become less noticeable but may not completely disappear, that hyperpigmentation is a relatively common complication, and that multiple treatments are typically required to achieve the desired effect. Thus, it is important for the clinician to document veins photographically prior to each treatment and to review these photographs with the patient periodically. (See <a class="local">'Timing of vein treatments'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h1">SCLEROTHERAPY AGENTS AND FORMULATIONS</span><span class="headingEndMark"> — </span>Sclerotherapy agents cause endothelial damage by their actions as either osmotic or detergent agents  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>). Osmotic agents achieve their effect by dehydrating endothelial cells through osmosis. Detergents are surface-active agents that damage the endothelium by interfering with cell membrane lipids [<a href="#rid15">15</a>]. In vitro, the detergent agents also exhibit procoagulant activity at lower concentrations and anticoagulant activity in higher concentrations [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H18905963"><span class="h2">Agents</span><span class="headingEndMark"> — </span>The most common sclerotherapy agents used in the treatment of lower extremity chronic venous disease are <a class="drug drug_general" data-topicid="9907" href="/d/drug information/9907.html" rel="external">polidocanol</a>, <a class="drug drug_general" data-topicid="10330" href="/d/drug information/10330.html" rel="external">sodium tetradecyl sulfate</a>, hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, and <a class="drug drug_general" data-topicid="8959" href="/d/drug information/8959.html" rel="external">glycerin</a>  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>). In the United States, only polidocanol and sodium tetradecyl sulfate are approved for this indication. Systematic reviews of randomized trials of sclerotherapy for telangiectasias, reticular veins, or small, nonaxial varicose veins have found no high-quality evidence to support the use of one sclerosant over another in the short-term success of injection sclerotherapy [<a href="#rid17">17-19</a>]. Agent selection is according to availability and clinician experience. However, there are some agent-specific advantages and differences in adverse reactions, which are detailed below [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Polidocanol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9907" href="/d/drug information/9907.html" rel="external">Polidocanol</a>, also known as aethoxysklerol, is a detergent. Polidocanol is available in a liquid or foam formulation. In one systematic review that compared various sclerotherapy agents, polidocanol was no more painful than placebo for the treatment of telangiectasias [<a href="#rid19">19</a>]. This is a significant advantage of this agent. The maximum dosage of polidocanol depends on the weight of the patient. Polidocanol concentrations of 0.5 and 1% were recommended for spider veins and reticular veins (&lt;3 mm), respectively, when polidocanol was initially approved for use in the US in 2010. Depending on the diameter of the treated vein, dilutions can be used, with concentrations lower than 1% used for narrower veins  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>). </p><p class="headingAnchor" id="H3016330896"><span class="h3">Sodium tetradecyl sulfate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10330" href="/d/drug information/10330.html" rel="external">Sodium tetradecyl sulfate</a> is a commonly studied sclerosant agent [<a href="#rid18">18</a>]. Dilutions between 0.1 and 3.0% are used depending on the diameter of the vein treated, with lower concentrations used for narrower veins  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>). Overall efficacy sodium tetradecyl sulfate appears to be similar to <a class="drug drug_general" data-topicid="9907" href="/d/drug information/9907.html" rel="external">polidocanol</a> [<a href="#rid15">15,20</a>]. However, some have suggested that sodium tetradecyl sulfate may cause more local adverse reactions. As an example, in a systematic review limited to treatment of telangiectasias, sodium tetradecyl sulfate at a concentration of 1% was more likely to cause complications compared with polidocanol at 0.5% [<a href="#rid19">19</a>]. In a later systematic review evaluating sclerotherapy for varicose veins, various agents, concentrations, and techniques produced similar results [<a href="#rid21">21</a>]. The maximum recommended dosage is 10 mL of a 3% solution in the US and Canada; the volume used varies worldwide depending on formulation. </p><p class="headingAnchor" id="H1583033839"><span class="h3">Hypertonic saline</span><span class="headingEndMark"> — </span>Hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> is an osmotic agent sometimes still used for lower extremity sclerotherapy, although not approved for use in the US. Dilutions between 11.7 and 23.4% are used depending on the diameter of the treated vein, with lower concentrations used for narrower veins  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>). Hypertonic saline is frequently mixed with local anesthetic to reduce the pain associated with injection (eg, 20% saline plus 2% <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>). </p><p>An agent that is a mixture of hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> (10%) and dextrose (25%), a relatively weak sclerosing agent, is also available (ie, Sclerodex); however, it has not been approved for use in the United States. </p><p class="headingAnchor" id="H168866740"><span class="h3">Glycerin</span><span class="headingEndMark"> — </span>Chromated <a class="drug drug_general" data-topicid="8959" href="/d/drug information/8959.html" rel="external">glycerin</a> is a potent osmotic sclerosant that is less commonly used for lower extremity sclerotherapy. Dilutions between 25 and 72% are used depending on the diameter of the vein treated, with lower concentrations used for narrower veins  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>). The maximum recommended amount per session is 10 mL [<a href="#rid22">22</a>]. While very popular worldwide, it is not commercially available in the US. </p><p class="headingAnchor" id="H4242653173"><span class="h2">Formulations</span><span class="headingEndMark"> — </span>Venous sclerotherapy agents can be formulated as a liquid or foam (ie, <a class="drug drug_general" data-topicid="9907" href="/d/drug information/9907.html" rel="external">polidocanol</a> endovenous microfoam or physician-compounded foam). For ablation of telangiectasis, reticular veins, or small, nonaxial varicose veins (&lt;6 mm) that can admit a 27- to 30-gauge needle, a liquid formulation is selected rather than foam to avoid the potential complications associated with foam. Liquid sclerotherapy can also be used to treat residual or recurrent veins following endovenous ablation or surgery, and perforator veins.</p><p>In principle, foam sclerotherapy can be used on all vein calibers, and vein clearance is probably similar [<a href="#rid17">17,23-29</a>]; however, a minority of practitioners would use a foam preparation for treating telangiectasias or reticular veins because it would subject the patient to potential risks (eg, matting, microembolism related to room air physician-compounded microfoam) without any additional benefit [<a href="#rid26">26,29-31</a>]. Therefore, foam sclerotherapy is predominantly applied to the treatment of reflux of the superficial axial veins (great, small, accessory saphenous) and reflux of perforator veins [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/129600.html" rel="external">"Nonthermal, nontumescent ablation techniques for the treatment of lower extremity superficial venous insufficiency", section on 'Sclerotherapy'</a> and  <a class="medical medical_review" href="/d/html/129600.html" rel="external">"Nonthermal, nontumescent ablation techniques for the treatment of lower extremity superficial venous insufficiency", section on 'Foam sclerotherapy technique'</a>.)</p><p class="headingAnchor" id="H2698107589"><span class="h1">TREATMENT APPROACH</span></p><p class="headingAnchor" id="H2347048274"><span class="h2">Timing of vein treatments</span><span class="headingEndMark"> — </span>Asymptomatic telangiectasias, reticular veins, and small, nonaxial varicose veins (&lt;6 mm) are frequently not associated with venous hypertension and can be treated as deemed necessary. Unless the veins have bled, their treatment is generally considered cosmetic. Several sessions are typically needed to fully treat and obliterate treated veins, with a minimum of six weeks between sessions. </p><p>When visibly dilated superficial veins are associated with typical symptoms (ie, pain, aching, swelling, fatigue), a venous duplex ultrasound is important to exclude axial venous insufficiency prior to treating the dilated superficial nonaxial veins. Sclerotherapy of nonaxial veins is not likely to be as effective, either initially or long-term, in the presence of persistent venous hypertension. To manage the associated nonaxial veins, clinicians may choose to handle residual veins at the same time as the superficial venous ablation or stage the procedures with phlebectomy or sclerotherapy at some interval following the ablation. (See  <a class="medical medical_review" href="/d/html/121344.html" rel="external">"Approach to treating symptomatic superficial venous insufficiency", section on 'Treatment timing'</a>.)</p><p class="headingAnchor" id="H1892462159"><span class="h1">TECHNIQUES AND FOLLOW-UP</span><span class="headingEndMark"> — </span>For patients with associated axial venous reflux, the axial vein is ablated prior to managing the nonaxial veins. (See <a class="local">'Sclerotherapy agents and formulations'</a> above and <a class="local">'Timing of vein treatments'</a> above.)</p><p>Telangiectasias, reticular veins, and small varicosities (&lt;6 mm) are treated using a liquid sclerosant, which is effective at eliminating the treated veins with high rates of patient satisfaction [<a href="#rid18">18,33,34</a>]. However, there is no consensus on specific aspects of sclerotherapy technique, including the type of sclerosing agent, use of local anesthetic, use or type of local compression pad, and use or duration of compression dressing (bandage or elastic). Typical sessions last from 15 to 60 minutes. </p><p>Clearance of treated telangiectasias, reticular veins, and small, nonaxial varicose veins can be expected but often requires serial treatment sessions. Recurrence of telangiectasias and reticular veins in the same area from recanalization is uncommon and most often is attributable to inadequate technique [<a href="#rid33">33,35</a>]. The development of new telangiectasias and reticular veins over time is more typical following sclerotherapy. Telangiectatic matting can occur but is typically due to a feeding reticular vein that has not been fully treated or eradicated. (See <a class="local">'Adverse reactions'</a> below.) </p><p class="headingAnchor" id="H722024726"><span class="h2">Injection method</span><span class="headingEndMark"> — </span>In general, the sclerosant liquid is mixed into a syringe at the appropriate concentration for the vein to be treated  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>). </p><p>The syringe is attached to a 27- or 30-gauge needle (sometimes a 33-gauge for the smallest telangiectasias), which is angled to assist its introduction into the vessel. The patient is placed in Trendelenburg position during injection to empty the vein of blood, which increases the contact time between the vein wall and the sclerosant. Following the application of alcohol to clean the area, the needle is introduced into the vein and with loss of resistance, which identifies the intraluminal needle placement, the sclerosant is then injected. </p><p>To treat telangiectasias, reticular veins, or small, nonaxial varicose veins (&lt;6 mm), the amount of liquid sclerosant that is injected depends on the size of the vein being treated  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>). Increasing concentrations and larger amounts are used for larger veins. When larger underlying reticular veins are identified, these are treated prior to addressing more superficial telangiectasias. A vein light (fiberoptic illuminator) is helpful for identifying reticular veins. Once the sclerosant has been injected, the needle is withdrawn and local compression and massage is used to keep blood out of the lumen of the vessel and to help disperse the sclerosant. Local compression pads (eg, mole foam, sorbo pads, dental bumpers, cotton balls) are placed and fixed with tape to maintain compression while moving on to the next vein. When vessels are treated sequentially from distal (ankle) to proximal (thigh) on the limb and from larger to smaller veins, over 90 percent of vessels can be successfully treated. </p><p>The procedure is terminated when the maximum volume of sclerosant has been injected  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>) or all the veins of interest have been treated. A light dressing is placed at the puncture sites, and graduated compression stockings or bandages (eg, Coban, Elastocrepe, Ace) are applied. (See <a class="local">'Compression therapy'</a> below.)</p><p>Providing no adverse reactions have occurred, the patient can be discharged. The patient is counseled to ambulate normally and may return to work.</p><p class="headingAnchor" id="H448211031"><span class="h2">Compression therapy</span><span class="headingEndMark"> — </span>Following injection sclerotherapy for telangiectasias, reticular veins, and small, nonaxial varicose veins (&lt;6 mm), we advise our patients to wear compression stockings continuously for 48 hours after treatment, after which time any local compression pads or bandages can be removed and compression stockings worn during the day (off at night and to bathe) for the next two weeks. Other regimens are used successfully, and this aspect of care remains a matter of debate. </p><p>A systematic review of older trials of injection sclerotherapy for varying sizes of varicose veins identified no differences in sclerotherapy success related to bandaging compared with elastic compression [<a href="#rid18">18</a>]. Bandaging &gt;72 hours did not provide advantages over short-term bandaging for cosmetic appearance or the incidence of superficial phlebitis or recurrent varicose veins. Short-term bandaging was also tolerated better than longer-term bandaging. </p><p>The benefit of compression stockings following sclerotherapy for telangiectasias and reticular veins has been documented in some, but not all [<a href="#rid36">36</a>], studies. Three trials suggested improved cosmetic outcomes with three weeks of compression stockings rather than shorter or no compression stockings following sclerotherapy of telangiectasias [<a href="#rid37">37-39</a>]. In one of these studies, a total of 40 patients with telangiectasias and/or reticular veins were treated with sclerotherapy [<a href="#rid38">38</a>]. Ten control patients did not receive compression stockings, while 30 patients in three groups of 10 received compression stockings for three days, one week, or three weeks. There was a correlation between the degree of improvement and length of time compression stockings were applied at 6, 12, and 24 weeks. Patients treated with compression stockings for three days or one week had significantly more improvement than control patients, while patients treated for three weeks had the most improvement.</p><p class="headingAnchor" id="H336045113"><span class="h2">Instructions</span><span class="headingEndMark"> — </span>Exercise is avoided for two weeks and treated areas should not be exposed to the sun during this period. Alternatively, sunscreen with a high sun protection factor (SPF ≥30) may be applied to the treated areas. </p><p>The patient should contact the clinician immediately if increasing pain is experienced or if any ulcerations appear at the injection sites. Repeat injections, which are frequently needed to manage varicosities within a specific region, are not performed for at least six weeks.</p><p>If a foam preparation has been used, the patient is also instructed to call their clinician if they experience unusual cough or visual, sensory, or motor disturbances. </p><p class="headingAnchor" id="H19"><span class="h1">ADVERSE REACTIONS</span><span class="headingEndMark"> — </span>The type of adverse reaction following injection sclerotherapy generally depends upon the sclerosing agent used  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>) [<a href="#rid18">18</a>]. </p><p>Common local adverse reactions to sclerosing agents include pain, ulceration, urticaria, hyperpigmentation, and telangiectatic matting  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>) [<a href="#rid40">40</a>]. A mild inflammatory response is expected after sclerotherapy, and some patients may have urticaria at the site of injection. A more intense superficial thrombophlebitis with erythema, warmth, and pain can extend to veins neighboring the injection site. Most local reactions are transient and resolve within months following the procedure [<a href="#rid41">41</a>]. </p><p>Allergic reactions to sclerosing agents occur in &lt;1 percent of patients, but anaphylaxis is rare [<a href="#rid42">42-44</a>]. In one large prospective multicenter registry of over 12,000 sclerotherapy sessions, anaphylaxis was not reported [<a href="#rid45">45</a>]. If a local or systematic reaction manifests, the sclerotherapy session should be terminated and standard protocols followed. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>Vasovagal reactions to the injections have also been reported. </p><p>Visual and other neurologic disturbances can occur, more typically following use of foam preparations. (See  <a class="medical medical_review" href="/d/html/129600.html" rel="external">"Nonthermal, nontumescent ablation techniques for the treatment of lower extremity superficial venous insufficiency", section on 'Sclerotherapy'</a> and  <a class="medical medical_review" href="/d/html/129600.html" rel="external">"Nonthermal, nontumescent ablation techniques for the treatment of lower extremity superficial venous insufficiency", section on 'Visual and other neurologic disturbances'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Minor pain</span><span class="headingEndMark"> — </span>Pain is common at the sclerotherapy injection site. Significant pain during injection may be an indication that the sclerosing agent has extravasated into the tissue around the vein. <a class="drug drug_general" data-topicid="9907" href="/d/drug information/9907.html" rel="external">Polidocanol</a> is associated with the least amount of pain upon injection [<a href="#rid18">18</a>], whereas hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and <a class="drug drug_general" data-topicid="8959" href="/d/drug information/8959.html" rel="external">glycerin</a> are the most painful, especially when used without <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Ulceration</span><span class="headingEndMark"> — </span>Ulcers may occur when the sclerosing agent extravasates from the vein into the subcutaneous tissue. The reported incidence is 1 to 5 percent of patients treated  (<a class="graphic graphic_picture graphicRef54891" href="/d/graphic/54891.html" rel="external">picture 3A</a>). Care must be taken to ensure that the needle is intraluminal before the sclerosant is injected. (See <a class="local">'Techniques and follow-up'</a> above.)</p><p>When ulcers occur, they are usually small and most often heal with local care in four to six weeks. However, they may result in scarring. <a class="drug drug_general" data-topicid="9907" href="/d/drug information/9907.html" rel="external">Polidocanol</a> is rarely associated with skin ulceration or necrosis because it is nontoxic to tissues [<a href="#rid15">15,41</a>].</p><p>Skin breakdown may also occur in response to excessive pressure from tape or compression garments [<a href="#rid40">40</a>].</p><p>Larger areas of skin necrosis may be related to retrograde flow of the sclerosant through an unexpected cutaneous arteriovenous malformation or the inadvertent injection of a small arteriole. This type of skin necrosis is rare and is independent of the type of sclerosant used.</p><p class="headingAnchor" id="H22"><span class="h2">Thrombus</span><span class="headingEndMark"> — </span>Thrombus forms within the vessel when blood contacts the sclerosing agent. The resulting mild inflammatory reaction is a source of post-treatment pain and is more common with treatment of reticular veins and small varicose veins compared with telangiectasias.</p><p>Microthrombectomy, which removes clot, significantly reduces postsclerotherapy pain and inflammation and in one multicenter randomized trial reduced hyperpigmentation in vessels smaller than one millimeter [<a href="#rid47">47</a>]. Microthrombectomy is typically performed at one to three weeks following treatment by making very small stab incisions (18- to 22-gauge needle or No. 65 Beaver blade) along the length of the thrombosed vein with aseptic technique. Thrombus is extruded by rolling a cotton-tipped applicator along the course of the vein, and the area is cleansed and dressed using sterile bandages. Topical local anesthesia is not usually necessary but may be helpful in some individuals.</p><p class="headingAnchor" id="H23"><span class="h2">Telangiectatic matting</span><span class="headingEndMark"> — </span>Telangiectatic matting consists of multiple, fine, dilated vessels in the area of the injection site  (<a class="graphic graphic_picture graphicRef74776" href="/d/graphic/74776.html" rel="external">picture 4</a>). It is relatively common, occurring in 15 to 24 percent of patients, and usually resolves within 3 to 12 months [<a href="#rid48">48</a>]. <a class="drug drug_general" data-topicid="10330" href="/d/drug information/10330.html" rel="external">Sodium tetradecyl sulfate</a> is associated with a lower incidence of telangiectatic matting [<a href="#rid18">18</a>].</p><p>In one retrospective review of 2120 patients, significantly more patients in the matting group were overweight, taking female hormones (estrogen, <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a>) during sclerotherapy treatment, and had both a family history and a longer duration of abnormal veins compared with the non-matting group [<a href="#rid48">48</a>]. </p><p>If a reticular vein can be identified feeding the area of matting, repeat sclerotherapy can be attempted; otherwise, the area can be treated with cutaneous laser once inflammation has subsided [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/8176.html" rel="external">"Laser and light therapy of lower extremity telangiectasias, reticular veins, and small varicose veins"</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Hyperpigmentation</span><span class="headingEndMark"> — </span>Hyperpigmentation occurs in up to 30 percent of patients following sclerotherapy  (<a class="graphic graphic_picture graphicRef54891 graphicRef55318" href="/d/graphic/54891.html" rel="external">picture 3A-B</a>). It is caused by deposition of hemosiderin in the skin as a result of extravasation of red blood cells. It usually becomes noticeable within one month following sclerotherapy and resolves spontaneously in 80 percent of patients within two years [<a href="#rid50">50</a>]. It occurs more commonly with treatment of veins greater than one millimeter in diameter and in patients with darker hair and Fitzpatrick skin types III through VI  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 1</a>) [<a href="#rid40">40</a>].</p><p>Hyperpigmentation is less frequent with <a class="drug drug_general" data-topicid="10330" href="/d/drug information/10330.html" rel="external">sodium tetradecyl sulfate</a>, and this agent is also associated with less bruising [<a href="#rid18">18</a>]. Treatment of telangiectasias with lower concentrations of <a class="drug drug_general" data-topicid="9907" href="/d/drug information/9907.html" rel="external">polidocanol</a> (0.5% versus 1%) reduced the incidence of hyperpigmentation with this agent [<a href="#rid44">44</a>]. </p><p>It is important for patients who experience hyperpigmentation to avoid sun exposure to the treated areas. Laser/light therapy may be tried in the treatment of postsclerotherapy hyperpigmentation, but the results are unpredictable, and occasionally pigmentation is worsened [<a href="#rid49">49,51</a>]. The treatment of cutaneous hyperpigmentation is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation"</a>.)</p><p>A technique called radiofrequency thermocoagulation may improve the cosmetic appearance after sclerotherapy. In a trial that randomized 111 patients to sclerotherapy alone or sclerotherapy followed by thermocoagulation, there was significantly less trapped blood and less hyperpigmentation in the group treated with thermocoagulation [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H2202191754"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118466.html" rel="external">"Society guideline links: Chronic venous disorders"</a>.)</p><p class="headingAnchor" id="H13803483"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/87610.html" rel="external">"Patient education: Vein ablation (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H37"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates for injection sclerotherapy</strong> – Injection sclerotherapy uses chemical irritants, which cause endothelial damage, to close unwanted superficial veins and is the treatment of choice for telangiectasias, reticular veins, and small, nonaxial, varicose veins (&lt;6 mm) large enough to admit a 27- or 30-gauge needle. Candidates are patients with persistent symptoms and signs of chronic venous disease refractory to medical management or those with recent (or recurrent) bleeding. (See <a class="local">'Indications'</a> above and  <a class="medical medical_review" href="/d/html/8181.html" rel="external">"Overview of lower extremity chronic venous disease", section on 'Approach by clinical severity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – Injection sclerotherapy is contraindicated in the presence of acute venous thrombosis (superficial or deep). Patients with risk factors for poor wound healing (eg, diabetes, peripheral artery disease) represent a relative contraindication. We also defer any treatment during pregnancy, since telangiectasias, reticular veins, and small, nonaxial varicose veins (&lt;6cmm) often regress after delivery. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Diagnostic studies are generally not necessary for asymptomatic individuals with telangiectasias, reticular veins, and small, nonaxial varicose veins (&lt;6 mm), which are often not associated with underlying venous reflux. For symptomatic patients, we suggest duplex ultrasound to identify superficial axial venous reflux, which alters treatment timing. (See <a class="local">'Treatment approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing associated axial venous reflux </strong>– When axial venous reflux is identified in conjunction with telangiectasias, reticular veins, or small, nonaxial varicose veins (&lt;6 mm), the axial vein is ablated prior to managing the nonaxial veins. (See <a class="local">'Timing of vein treatments'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulations </strong>– Agent selection  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>) is according to availability and clinician experience. For ablation of telangiectasis, reticular veins, or small, nonaxial varicose veins (&lt;6 mm diameter) that can admit a 27- to 30-gauge needle, we suggest liquid sclerotherapy rather than foam sclerotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Foam sclerosing agents subject the patient to potential risks without any added benefit. (See <a class="local">'Sclerotherapy agents and formulations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Techniques</strong> – There is no consensus on specific aspects of sclerotherapy technique. Following injection sclerotherapy, compression pads/bandages are left in place at the sclerotherapy sites. We advise our patients to wear compression stockings continuously for 48 hours to reduce pain and bruising, after which time the compression pads/bandages are removed. Subsequently, compression stockings are worn during the day for at least two weeks. (See <a class="local">'Techniques and follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse reactions and</strong> <strong>recurrence</strong> – Common adverse reactions include pain or ulceration at the injection site, localized thrombus, telangiectatic matting, and hyperpigmentation, the frequency of which depend upon the agent used  (<a class="graphic graphic_table graphicRef70171" href="/d/graphic/70171.html" rel="external">table 2</a>). More severe complications are rare. New telangiectasias and reticular veins commonly develop over time. (See <a class="local">'Adverse reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postprocedure instructions</strong> – Following injection sclerotherapy, we advise exercise avoidance for two weeks, and treated areas should not be exposed to the sun. Minor pain is common at the injection sites. The clinician should be contacted immediately for increasing pain or development of ulceration at the injection site. Follow-up treatment may include microthrombectomy to evacuate any accumulated thrombus in the treated veins. (See <a class="local">'Compression therapy'</a> above and <a class="local">'Instructions'</a> above and <a class="local">'Adverse reactions'</a> above.)</p><p></p><p class="headingAnchor" id="H97429439"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Deborah Greenberg, MD, FACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Eklöf B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40:1248.</a></li><li><a class="nounderline abstract_t">Langer RD, Ho E, Denenberg JO, et al. Relationships between symptoms and venous disease: the San Diego population study. Arch Intern Med 2005; 165:1420.</a></li><li><a class="nounderline abstract_t">Criqui MH, Jamosmos M, Fronek A, et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. Am J Epidemiol 2003; 158:448.</a></li><li><a class="nounderline abstract_t">Labas P, Cambal M. Profuse bleeding in patients with chronic venous insufficiency. Int Angiol 2007; 26:64.</a></li><li><a class="nounderline abstract_t">Hamahata A, Yamaki T, Osada A, et al. Foam sclerotherapy for spouting haemorrhage in patients with varicose veins. Eur J Vasc Endovasc Surg 2011; 41:856.</a></li><li><a class="nounderline abstract_t">Tretbar LL. Treatment of small bleeding varicose veins with injection sclerotherapy. Bleeding blue blebs. Dermatol Surg 1996; 22:78.</a></li><li><a class="nounderline abstract_t">Rabe E, Pannier F, for the Guideline Group. Indications, contraindications and performance: European Guidelines for Sclerotherapy in Chronic Venous Disorders. Phlebology 2014; 29:26.</a></li><li><a class="nounderline abstract_t">Rabe E, Pannier F. Sclerotherapy of varicose veins with polidocanol based on the guidelines of the German Society of Phlebology. Dermatol Surg 2010; 36 Suppl 2:968.</a></li><li><a class="nounderline abstract_t">Reich-Schupke S, Leiste A, Moritz R, et al. Sclerotherapy in an undetected pregnancy - a catastrophe? Vasa 2012; 41:243.</a></li><li class="breakAll">Varithena prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205098s000lbl.pdf (Accessed on January 13, 2022).</li><li><a class="nounderline abstract_t">Abramowitz I. The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. S Afr Med J 1973; 47:607.</a></li><li><a class="nounderline abstract_t">Lupton JR, Alster TS, Romero P. Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatol Surg 2002; 28:694.</a></li><li><a class="nounderline abstract_t">Coles CM, Werner RS, Zelickson BD. Comparative pilot study evaluating the treatment of leg veins with a long pulse ND:YAG laser and sclerotherapy. Lasers Surg Med 2002; 30:154.</a></li><li><a class="nounderline abstract_t">Hafner F, Froehlich H, Gary T, Brodmann M. Intra-arterial injection, a rare but serious complication of sclerotherapy. Phlebology 2013; 28:64.</a></li><li><a class="nounderline abstract_t">Goldman MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatol Surg 2002; 28:52.</a></li><li><a class="nounderline abstract_t">Parsi K, Exner T, Connor DE, et al. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. Eur J Vasc Endovasc Surg 2007; 34:731.</a></li><li><a class="nounderline abstract_t">Nakano LC, Cacione DG, Baptista-Silva JC, Flumignan RL. Treatment for telangiectasias and reticular veins. Cochrane Database Syst Rev 2021; 10:CD012723.</a></li><li><a class="nounderline abstract_t">Tisi PV, Beverley C, Rees A. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev 2006; :CD001732.</a></li><li><a class="nounderline abstract_t">Schwartz L, Maxwell H. Sclerotherapy for lower limb telangiectasias. Cochrane Database Syst Rev 2011; :CD008826.</a></li><li><a class="nounderline abstract_t">Rao J, Wildemore JK, Goldman MP. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatol Surg 2005; 31:631.</a></li><li><a class="nounderline abstract_t">de Ávila Oliveira R, Riera R, Vasconcelos V, Baptista-Silva JC. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev 2021; 12:CD001732.</a></li><li><a class="nounderline abstract_t">Leach BC, Goldman MP. Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatol Surg 2003; 29:612.</a></li><li><a class="nounderline abstract_t">Bi M, Li D, Chen Z, et al. Foam sclerotherapy compared with liquid sclerotherapy for the treatment of lower extremity varicose veins: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2020; 99:e20332.</a></li><li><a class="nounderline abstract_t">Hoss E, Kollipara R, Boen M, et al. Comparison of the Safety and Efficacy of Foam Sclerotherapy With 1: 2 Polidocanol to Air Ratio Versus 1: 4 Ratio for the Treatment of Reticular Veins of the Lower Extremities. Dermatol Surg 2020; 46:1715.</a></li><li><a class="nounderline abstract_t">Hamel-Desnos C, Allaert FA. Liquid versus foam sclerotherapy. Phlebology 2009; 24:240.</a></li><li><a class="nounderline abstract_t">Kern P, Ramelet AA, Wutschert R, et al. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg 2004; 30:367.</a></li><li><a class="nounderline abstract_t">Uncu H. Sclerotherapy: a study comparing polidocanol in foam and liquid form. Phlebology 2010; 25:44.</a></li><li><a class="nounderline abstract_t">Kaygin MA, Halici U. Evaluation of liquid or foam sclerotherapy in small varicose veins (ceap c1) with venous clinical severity score. Rev Assoc Med Bras (1992) 2018; 64:1117.</a></li><li><a class="nounderline abstract_t">Alòs J, Carreño P, López JA, et al. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. Eur J Vasc Endovasc Surg 2006; 31:101.</a></li><li><a class="nounderline abstract_t">Willenberg T, Smith PC, Shepherd A, Davies AH. Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review. Phlebology 2013; 28:123.</a></li><li><a class="nounderline abstract_t">Guex JJ, Schliephake DE, Otto J, et al. The French polidocanol study on long-term side effects: a survey covering 3,357 patient years. Dermatol Surg 2010; 36 Suppl 2:993.</a></li><li><a class="nounderline abstract_t">Breu FX, Guggenbichler S. European Consensus Meeting on Foam Sclerotherapy, April, 4-6, 2003, Tegernsee, Germany. Dermatol Surg 2004; 30:709.</a></li><li><a class="nounderline abstract_t">Labas P, Ohradka B, Cambal M, et al. Long term results of compression sclerotherapy. Bratisl Lek Listy 2003; 104:78.</a></li><li><a class="nounderline abstract_t">Weiss RA, Weiss MA. Resolution of pain associated with varicose and telangiectatic leg veins after compression sclerotherapy. J Dermatol Surg Oncol 1990; 16:333.</a></li><li><a class="nounderline abstract_t">Bradbury AW, Bate G, Pang K, et al. Ultrasound-guided foam sclerotherapy is a safe and clinically effective treatment for superficial venous reflux. J Vasc Surg 2010; 52:939.</a></li><li><a class="nounderline abstract_t">Bayer A, Kuznik N, Langan EA, et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. J Vasc Surg Venous Lymphat Disord 2021; 9:435.</a></li><li><a class="nounderline abstract_t">Kern P, Ramelet AA, Wütschert R, Hayoz D. Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. J Vasc Surg 2007; 45:1212.</a></li><li><a class="nounderline abstract_t">Weiss RA, Sadick NS, Goldman MP, Weiss MA. Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome. Dermatol Surg 1999; 25:105.</a></li><li><a class="nounderline abstract_t">Nootheti PK, Cadag KM, Magpantay A, Goldman MP. Efficacy of graduated compression stockings for an additional 3 weeks after sclerotherapy treatment of reticular and telangiectatic leg veins. Dermatol Surg 2009; 35:53.</a></li><li><a class="nounderline abstract_t">Munavalli GS, Weiss RA. Complications of sclerotherapy. Semin Cutan Med Surg 2007; 26:22.</a></li><li><a class="nounderline abstract_t">Weiss RA, Weiss MA. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol. J Dermatol Surg Oncol 1990; 16:800.</a></li><li><a class="nounderline abstract_t">Cavezzi A, Parsi K. Complications of foam sclerotherapy. Phlebology 2012; 27 Suppl 1:46.</a></li><li><a class="nounderline abstract_t">Frullini A, Cavezzi A. Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications. Dermatol Surg 2002; 28:11.</a></li><li><a class="nounderline abstract_t">Norris MJ, Carlin MC, Ratz JL. Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. J Am Acad Dermatol 1989; 20:643.</a></li><li><a class="nounderline abstract_t">Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005; 31:123.</a></li><li><a class="nounderline abstract_t">Bukhari RH, Lohr JM, Paget DS, et al. Evaluation of lidocaine as an analgesic when added to hypertonic saline for sclerotherapy. J Vasc Surg 1999; 29:479.</a></li><li><a class="nounderline abstract_t">Scultetus AH, Villavicencio JL, Kao TC, et al. Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial. J Vasc Surg 2003; 38:896.</a></li><li><a class="nounderline abstract_t">Davis LT, Duffy DM. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis. J Dermatol Surg Oncol 1990; 16:327.</a></li><li><a class="nounderline abstract_t">Bernstein EF. Clinical characteristics of 500 consecutive patients presenting for laser removal of lower extremity spider veins. Dermatol Surg 2001; 27:31.</a></li><li><a class="nounderline abstract_t">Goldman MP, Kaplan RP, Duffy DM. Postsclerotherapy hyperpigmentation: a histologic evaluation. J Dermatol Surg Oncol 1987; 13:547.</a></li><li><a class="nounderline abstract_t">Glaich AS, Goldberg LH, Dai T, Friedman PM. Fractional photothermolysis for the treatment of telangiectatic matting: a case report. J Cosmet Laser Ther 2007; 9:101.</a></li><li><a class="nounderline abstract_t">Diken Aİ, Alemdaroğlu U, Özyalçın S, et al. Adjuvant radiofrequency thermocoagulation improves the outcome of liquid sclerotherapy in the treatment of spider veins of the leg: A pilot study. Phlebology 2021; 36:620.</a></li></ol></div><div id="topicVersionRevision">Topic 8206 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15622385" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Revision of the CEAP classification for chronic venous disorders: consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983292" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Relationships between symptoms and venous disease: the San Diego population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12936900" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chronic venous disease in an ethnically diverse population: the San Diego Population Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353890" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Profuse bleeding in patients with chronic venous insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420881" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Foam sclerotherapy for spouting haemorrhage in patients with varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8556262" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of small bleeding varicose veins with injection sclerotherapy. Bleeding blue blebs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24843082" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Indications, contraindications and performance: European Guidelines for Sclerotherapy in Chronic Venous Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20590702" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Sclerotherapy of varicose veins with polidocanol based on the guidelines of the German Society of Phlebology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22825857" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sclerotherapy in an undetected pregnancy - a catastrophe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22825857" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Sclerotherapy in an undetected pregnancy - a catastrophe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4701297" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174060" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870796" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparative pilot study evaluating the treatment of leg veins with a long pulse ND:YAG laser and sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22422795" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intra-arterial injection, a rare but serious complication of sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11991271" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919946" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : In vitro effects of detergent sclerosants on coagulation, platelets and microparticles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34637138" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment for telangiectasias and reticular veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054141" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Injection sclerotherapy for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161437" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sclerotherapy for lower limb telangiectasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996411" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34883526" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Injection sclerotherapy for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12786704" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32481409" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Foam sclerotherapy compared with liquid sclerotherapy for the treatment of lower extremity varicose veins: A protocol for systematic review and meta analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32947299" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of the Safety and Efficacy of Foam Sclerotherapy With 1: 2 Polidocanol to Air Ratio Versus 1: 4 Ratio for the Treatment of Reticular Veins of the Lower Extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952379" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Liquid versus foam sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15008862" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20118346" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sclerotherapy: a study comparing polidocanol in foam and liquid form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30569988" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Evaluation of liquid or foam sclerotherapy in small varicose veins (ceap c1) with venous clinical severity score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16226901" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23761921" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20590706" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The French polidocanol study on long-term side effects: a survey covering 3,357 patient years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15099312" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : European Consensus Meeting on Foam Sclerotherapy, April, 4-6, 2003, Tegernsee, Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12839217" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long term results of compression sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2324369" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Resolution of pain associated with varicose and telangiectatic leg veins after compression sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20638224" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ultrasound-guided foam sclerotherapy is a safe and clinically effective treatment for superficial venous reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32502730" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17467226" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037513" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19067733" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy of graduated compression stockings for an additional 3 weeks after sclerotherapy treatment of reticular and telangiectatic leg veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349559" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Complications of sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2398199" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22312067" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Complications of foam sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11991262" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2654207" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15762201" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10069912" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Evaluation of lidocaine as an analgesic when added to hypertonic saline for sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14603191" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691217" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231238" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical characteristics of 500 consecutive patients presenting for laser removal of lower extremity spider veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3571692" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Postsclerotherapy hyperpigmentation: a histologic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17558760" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fractional photothermolysis for the treatment of telangiectatic matting: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33813962" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Adjuvant radiofrequency thermocoagulation improves the outcome of liquid sclerotherapy in the treatment of spider veins of the leg: A pilot study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
